Amanta Healthcare IPO GMP: The initial public offering of Amanta Healthcare Ltd is going to be closed today, Wednesday, September 3. The price of the Rs 126-crore IPO has been fixed in the range of Rs 120
to Rs 126 per share. Till 11:10 am on the final day of bidding on Wednesday, the issue received a 31.04x subscription, garnering bids for 21,72,90,192 shares as against the 70,00,000 shares on offer.
The retail and NII participation stood at 32.37x and 68.29x, respectively. The QIB category was subscribed by 0.78x.
The IPO’s grey market premium stood at 9.52%, indicating a modest listing potential.
Amanta Healthcare IPO Price And Lot Size
The price of the IPO has been fixed in the range of Rs 120 to Rs 126 per share.
For investors, the minimum lot size for the IPO is 119. It means investors will have to apply for a minimum of 119 shares or in multiple thereof. So, retail investors require a minimum capital of Rs 14,994 to apply for the IPO.
Amanta Healthcare IPO Key Dates
The IPO will remain open for public subscription between September 1, 2025, and September 3, 2025. The share allotment will likely be finalised on September 4, while the company is expected to be listed on both BSE and NSE on September 9.
Amanta Healthcare IPO GMP Today
According to market observers, unlisted shares of Amanta Healthcare Ltd are currently trading at Rs 138 against the upper IPO price of Rs 126. It means a grey market premium or GMP of Rs 12, which is 9.52% over its issue price, indicating modest listing gains for investors.
The GMP is based on market sentiments and keeps changing. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.
Amanta Healthcare IPO: More Details
The Rs 126-crore IPO is entirely a fresh issue of 1 crore shares.
Beeline Capital Advisors is the book-running lead manager to the offer.
Amanta Healthcare Ltd’s revenue fell 2% and profit after tax (PAT) rose 189% between the financial year ending with March 31, 2025, and March 31, 2024.
AHL is engaged in developing/manufacturing/marketing diverse range of sterile liquid pharma products. It posted almost static top lines for the reported periods. It suffered for FY23 and FY24 on account MAT incentive reversals and other related adjustments. It is operating in a highly competitive and fragmented segment.
Based on its recent financial data, the issue appears exorbitantly priced. Only well-informed/cash surplus investors may park moderate funds for medium term/ others can stay away.
